We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


European Launch of new System for Molecular Diagnostics

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "European Launch of new System for Molecular Diagnostics"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The BD MAX system enables users to develop their own fully-automated assays on the open-architecture system. The system was unveiled at the European Congress of Clinical Microbiology and Infectious Diseases.

“The increasing prevalence of infectious and drug-resistant organisms and their migration into healthcare facilities warrants faster, easier and more comprehensive testing with flexible workflows that accommodate each institution’s unique needs,” said Philippe Jacon, President, BD Diagnostics – Diagnostic Systems.  “The BD MAX System will help hospitals and laboratories meet their expanding needs for screening and testing for these pathogens.”

The BD MAX System offers a unique combination of simplicity, flexibility, scalability and lab efficiency.  The system can be operated by any lab technician and does not require specialised molecular skills or lab facilities. It can concurrently process different assays for up to 24 patient samples typically producing results within two and half hours.  It can also provide on-demand processing of up to four samples in under 90 minutes.

MAX System option 3 copy.gif

BD MAX System for Molecular Diagnostics

With hands-off operation and true walk away time, the system frees technicians to perform other tasks during a run, improving laboratory efficiency and productivity. The open platform design and general purpose reagents offer maximum flexibility for implementation of fully-automated laboratory developed assays for DNA and RNA testing.  The availability of the CE marked      BD MAX Assay for detection of Group B Streptococci in pregnant women will help enable clinicians to take appropriate action to colonized patients to minimize the risk of infection to the mother or infant at childbirth.